Report Overview

The global dilated cardiomyopathy market was pegged US$ 0.2 billion in 2021 and is expected to witness a CAGR of 5.2% during the forecast period.

Market Fundamentals 

Dilated cardiomyopathy (DCM) is a disorder that affects the heart's muscles, causing enlargement and dilation of one or both ventricles as well as decreased contractility, which is indicated by a left ventricular ejection fraction (LVEF) of less than 40%. Normally, dilated cardiomyopathy leads to cardiac failure and death. Without a transplant, the prognosis for dilated cardiomyopathy is poor. There are several dilated cardiomyopathy causes, and each one has a different impact on cardiac function. While most people with dilated cardiomyopathy experience symptoms, others may not because of compensatory mechanisms.

Ventricular function decreases when the ventricles expand, and this is followed by abnormalities of the conduction system, ventricular arrhythmias, thromboembolism, and heart failure. For the diagnosis of dilated cardiomyopathy, a number of tests are employed, including blood tests, CT scans, MRI scans, ECGs, and others.

[3442233]

Market Dynamics

The market for dilated cardiomyopathy is expanding primarily because cardiac disease have become more common and life expectancy is increasing. A rise in the number of people with cardiac muscle diseases and drug and alcohol abusers is another factor driving the market forward. The incidence of cardiovascular disease is increasing, which is directly related to market growth. Due to expanding medical tourism in developing countries and increased research and development for cardiomyopathy treatments, there are also numerous potentials for the development of the cardiomyopathy market. However, the main issues limiting the market growth are thought to be the high cost of diagnosis and treatment as well as the general lack of public awareness.

Market Ecosystem

The global dilated cardiomyopathy market has been analyzed by four perspectives by drugs, devices, end user and region.

Dilated Cardiomyopathy Market by Drugs

[122211122]

Based on drugs, the global dilated cardiomyopathy market has been analyzed into blood thinning medications, beta blockers, cardiac glycosides, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. The angiotensin II receptor blockers segment dominated the global market during forecast period. This is attributed to increased demand for blockbuster drugs in the treatment of dilated cardiomyopathy, particularly in developed nations.

Dilated Cardiomyopathy Market by End User

Based on end user, the global dilated cardiomyopathy market has been analyzed into hospital, retail, and online pharmacies. The retail pharmacies held the largest share due to greater patient footfall and higher popularity in Asia Pacific and rest of the world markets. 

Dilated Cardiomyopathy Market by Region

Based on the region, the global dilated cardiomyopathy market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is anticipated to dominate the dilated cardiomyopathy market for the entire forecast period. Presence of state-of-the-art healthcare infrastructure, well-structured and favourable insurance programmes are key characteristics of the North American market.

Because of the high demand for generic drugs, the improving standard of living, large population base and growing healthcare expenditures and awareness, the markets in Asia Pacific and the rest of the world are growing at the fastest rates. Moreover, due to the high prevalence of diseases like cancer and cardiovascular issues, India and China represent attractive areas for the growth of the dilated cardiomyopathy industry.

Competitive Landscape

Some of the prominent plyers in the global dilated cardiomyopathy market include 

• Array BioPharma
• Vericel Corporation
• PhaseBio Pharmaceuticals
• Celladon Corporation 
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson and Johnson Pvt. Ltd. 
• Merck & Co., Inc 
• Teva Pharmaceuticals 
• t2cure GmbH,
• Astrazeneca plc 
• Sanofi S.A.
• Vericel Corporation
• Janssen Pharmaceuticals, Inc.

 Industry participants are using a variety of strategies to stay competitive in the market, including mergers and acquisitions, partnerships, collaborations, funding, and the introduction of new drugs, which are greatly boosting market growth. For instance, in February 2020, Renovacor collaborated with the Heart Failure Society of America, the American Association of Heart Failure Nurses (AAHFN), and the Dilated Cardiomyopathy (DCM) Foundation (HFSA). Through their collaboration, the patient and provider communities will learn more about cardiomyopathies and the risk factors associated with them.

Strategic Developments

• In October 2020, for $13.1 billion, Bristol Myers Squibb acquired MyoKardia Inc. in order to fully investigate the potential of mavacamten in other indications, such as non-obstructive HCM. The acquisition was made to treat obstructive hypertrophic cardiomyopathy with a potential first-in-class cardiovascular drug. The U.S. Food and Drug Administration must receive a submission of the new medication (FDA).
• In August 2019, the 2nd Annual Myoseeds Research Grant was created by MyoKardia, Inc. to encourage independent biological research and to comprehend the mechanism of cardiomyopathies and its therapy.
• In March 2019, The Dilated Cardiomyopathy Foundation in Ohio has announced the launch of a website to raise awareness of the ailment and inform patients and their loved ones about how to manage their heart condition. DCM has a wide range of known causes, and it affects about 1 in 250 persons. There have been numerous reports of persons who have idiopathic DCM, or DCM with an unidentified cause. As a result, genetic factors are thought to be a major influence in idiopathic DCM; therefore, the DCM foundation has worked with the DCM Research Project, which is supported by the National Institutes of Health, to discover this relationship. The results are always made available on the DCM website.

Frequently Asked Questions About This Report